• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

First European patients treated with BTG’s drug-eluting bead

April 20, 2017 By Sarah Faulkner

BTG BTG (LON:BTG) said today that the 1st batch of patients in the European Union were treated with its DC Bead Lumi radiopaque drug-eluting bead. Two patients were treated for hepatocellular carcinoma and 1 patient was treated for malignant colorectal cancer metastasized to the liver.

The bead, which is the 1st commercially available radiopaque drug-eluting bead in the EU, uses doxorubicin or irinotecan to locally treat tumors.

The company’s DC Bead Lumi also features real-time visible confirmation of the bead’s location, which the company claims will enhance control in transarterial chemoembolisation procedures.

The bead can be seen during and after embolisation, which enables doctors to individualize a patient’s treatment and evaluate the completeness of tumor treatment, according to BTG.

“We are very pleased with the results from treatment in our patients, and DC Bead Lumi offered clear, real-time evidence on the treatment of the target lesion while the long-term radiopacity means not only can we see where we are delivering the treatment during the procedure, but we can also identify areas of successful treatment – or under treatment – in follow up scans.” Dr. Camillo Aliberti, from the Instituto Oncologico Veneto, said in prepared remarks.

“DC Bead Lumi provides the opportunity to individualize a patient’s treatment and bring a new level of control to [transarterial chemoembolisation] procedures. At the same time, the lasting radiopacity allows you to see rather than assume the location of the beads, providing reassurance to patients that the treatment is getting to where it needs to be.” commented Duncan Kennedy, BTG Head of Interventional Oncology. “DC Bead Lumi is the latest step of BTG Interventional Oncology’s strategy to discover and develop differentiated therapeutic innovations. The feedback from the treatment of the 1st patients indicates that DC Bead Lumi is an important advance in personalized, loco-regional cancer therapies. We’re proud to offer an innovative new treatment option for patients and clinicians and look forward to providing DC Bead Lumi to more clinicians across the EU.”

The drug-eluting bead won CE Mark clearance in March.

Filed Under: Drug-Device Combinations, Featured, Oncology, Wall Street Beat Tagged With: BTG

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS